Euclidean Capital LLC Rapt Therapeutics, Inc. Transaction History
Euclidean Capital LLC
- $906 Million
- Q3 2024
A detailed history of Euclidean Capital LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Euclidean Capital LLC holds 657,899 shares of RAPT stock, worth $578,951. This represents 0.15% of its overall portfolio holdings.
Number of Shares
657,899
Previous 657,899
-0.0%
Holding current value
$578,951
Previous $2.01 Million
34.1%
% of portfolio
0.15%
Previous 0.25%
Shares
5 transactions
Others Institutions Holding RAPT
# of Institutions
104Shares Held
27.1MCall Options Held
26.7KPut Options Held
2.4K-
Vanguard Group Inc Valley Forge, PA3.16MShares$2.78 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$2.36 Million7.75% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$2.15 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$1.52 Million0.42% of portfolio
-
Ponoi Management, LLC San Francisco, CA1.6MShares$1.41 Million52.54% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $26.1M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...